A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

Phase 3 Active not recruiting 1390 enrolled Vaxcyte, Inc.

RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a Phase 3, randomized, double-blind study to evaluate the safety and immunogenicity of VAX-31 and seasonal influenza vaccine in pneumococcal-naïve adults ≥ 50 years when the two vaccines are administered at the same visit or separately.

Timeline

Start: 2026-01-12
Primary completion: 2027-03
Completion: 2027-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Flublok	Vaccine	0.5 ml	Intramuscular
Subject	VAX-31	Vaccine	0.5 ml	Intramuscular

Indications

No indication recorded.